银发经济或成下一个风口(共8份)
银发经济或成下一个风口
-
艾媒咨询|2020H1中国冷链物流产业应用及典型案例研究报告
本报告研究涉及企业/品牌/案例:京东物流、海容冷链、冰山冷热、苏宁冷链。
在居民生活品质意识加强及物流产业发展日渐成熟的推动下,中国冷链物流市场规模不断扩大,2019年冷链物流市场规模已达3780亿元,并预计在2020年达到4850亿元。同时,中国冷链物流企业数量持续增长,在2019年达到了1832家,但存在着地域分布不均的问题,32.3%的企业集中在华东地区。目前冷链物流产业主要应用于食品及医药两大产品线。iiMedia Research(艾媒咨询)数据显示,2020年中国生鲜电商交易规模超过2600亿元,而医药物流市场预计在2020年达到3.8万亿元,并且预计未来冷链物流产业将开拓出新的产品线,冷链物流市场潜力较大。面对“新冠疫情”居家隔离政策下爆发的配送需求,冷链物流企业通过扩大运输网络及车辆仓储资源,同时深化信息技术的应用提高配送效能及服务体验。
Driven by people’s increasing awareness of living standard along with the development of logistics industry, the scale of China cold chain logistics market has enlarged continually, which has reached 378 billion RMB in 2019, and is expected to reach 485 billion RMB in 2020. At the same time, the number of cold chain logistics enterprises in China has increased constantly, which has reached the number of 1832 in 2019. However, there is a problem of uneven distribution, as 32.3% of the enterprises are located in the Eastern China. So far, there are two main product lines for the application of cold chain logistics, which are food and pharmaceuticals. As the data of iiMedia Research showed, the scale of China fresh food e-commerce market transaction is expected to be over 260 billion RMB, while the market scale of China pharmaceutical logistics is expected to be 3800 billion RMB in 2020, and other new product lines are also expected to be explored in the future, so the market potential of cold chain logistics is substantial. To face with the demand exposure of delivery under the policy of stay home quarantine within the “COVID-19” period, the cold chain logistics enterprises improved their delivery efficiency and customers’ service experience by expanding their delivery network, increasing the vehicles and storage resources, as well as further the application of information technology. -
艾媒报告|2019中国即时配送市场研究报告
本报告研究涉及企业/品牌/案例:美团点评、UU跑腿、邻趣、快服务、闪送、阿里巴巴集团、蚂蚁金服集团、饿了么,菜鸟网络,顺丰,天猫,东方汇富、汇德丰、因诺资产、新达达,沃尔玛,京东,苏宁,点我达,盒马、银泰、屈臣氏、世纪联华、大润发、星巴克、瑞幸咖啡
即时配送服务在新零售概念的推行下迅速普及,其通过打通线上线下销售,建立短途物流体系,解决传统配送服务中同城配送的问题,已成为商业发展的必然趋势。2018年中国即时配送市场用户规模继续稳定增长。iiMedia Research(艾媒咨询)数据显示,2018年中国即时配送用户规模达到3.58亿人,预计2019年突破4亿人。新零售业务无疑是即时配送行业发展的重要增长点。在关于即时配送用户使用的服务品类调查中,下单生鲜水果、日用品、鲜花、文件资料等服务的用户占比均超过20%。而用户偏好新零售业务中,偏好下单如医药健康等其他品类即时配送服务的用户较2017年第一季度上升了106.1%。
With the spread of New Retail concept, the immediate delivery service has been rapidly popularized. As it solve the in-city delivery problem which emerge in the traditional delivery services by opening up online-offline sales and establishing the short-distance logistics system, it has become an inevitable trend of commercial development. In 2018, the scale of China Immediate Delivery users continued to grow steadily. As the data of iiMedia Research showed, the scale of the users has reached 358 million, and expected to exceed 400 million in 2019. New retail business is undoubtedly an important growth point in the development of Immediate Delivery industry. The results of the survey for services used by immediate delivery users showed that, the proportion of users who had relatively ordered fresh fruits, daily necessities, flowers, documents and etc. are all greater than 20%. As for the new retail services, users who prefer other types of immediate delivery services, such as medicine delivery, increased by 106.1% compared with the one in the first quarter of 2017. -
艾媒咨询|2021全球与中国医药电商市场与发展趋势研究报告
本报告研究涉及企业/品牌/案例:阿里健康,美团,京东健康,叮当快药,1药网,Walgreens,百度健康,药材买卖网,中药材天地网,找药网,九州通,药易购,珍诚医药在线,CVS
在政策利好、互联网技术等多重因素推动下,中国医药电商行业规模持续快速发展,2020年中国医药电商市场交易规模达到1956亿元。当前,中药电商商业模式主要为B2B、B2C、O2O与DTP四种类型,其中,2020年,医药电商B2C模式占比近6%,市场规模为116亿元;医药电商B2C模式占比近84%,市场规模为1640亿元,成为当前的主流。此外,近几年兴起的O2O模式,主要通过“引流-转化-消费-反馈”等实现盈利,而DTP药房模式下,患者在医院开取处方后,药房根据处方以患者或家属指定的时间和地点送药上门,被称为高值新特药直送平台。
Driven by favorable policies, Internet technology and other factors, the scale of China's pharmaceutical e-commerce industry continues to develop rapidly, with the transaction scale of China's pharmaceutical e-commerce market reaching 1956 billion yuan in 2020. At present, the business models of traditional Chinese medicine e-commerce are mainly B2B, B2C, o2o and DTP. In 2020, the B2C model of pharmaceutical e-commerce accounts for nearly 6% and the market scale is 11.6 billion yuan; the B2C model of pharmaceutical e-commerce accounts for nearly 84% and the market scale is 164 billion yuan, which has become the current mainstream. In addition, the o2o mode, which has sprung up in recent years, mainly achieves profits through "drainage transformation consumption feedback". In the DTP pharmacy mode, after patients get prescriptions in the hospital, the pharmacy delivers drugs to the door at the time and place designated by the patients or their families according to the prescriptions, which is known as the high value new special drugs direct delivery platform. -
艾媒咨询|2021-2022年中国医美器械产业运行及投资决策分析报告
本报告研究涉及企业/品牌/案例:科医人,复星医药,奇致激光,半岛医疗
伴随着医美市场规模的持续扩大,中国医美器械行业发展前景可期。数据显示,预计2021年中国医美器械市场规模将超过500亿元,同比增长27.8%。从细分赛道来看,近年来,微创和无创已逐渐成为医疗美容的趋势,这就推动了以激光、超声波等能量源为代表的光电类医美器械的发展。从市场格局来看,中国正规医美机构设备的市场份额80%是进口品牌,且中高端市场被飞顿、塞诺龙等海外龙头企业占领。为了改变这一局面,国家及地方先后出台政策鼓励本土医美器械品牌的发展,同时,国有品牌也通过加大自主研发投入和投资并购来扩大市场份额,未来随着下游扩张、需求渗透、技术更新等因素有望加速进口替代。
With the continuous expansion of the medical beauty market, the development prospect of the medical beauty equipment industry in China is promising. According to the data, it is estimated that in 2021, the market size of medical devices in China will exceed 50 billion yuan, with a year-on-year growth of 27.8%. From the perspective of subdivision, in recent years, minimally invasive and non-invasive have gradually become the trend of medical beauty, which promotes the development of photoelectric medical beauty devices represented by laser, ultrasonic and other energy sources. From the perspective of market structure, 80% of the market share of China's regular medical and beauty institutions' equipment is imported brands, and the medium and high-end market is occupied by overseas leading enterprises such as feton and sinolon. In order to change this situation, the state and local governments have successively issued policies to encourage the development of local medical and beauty equipment brands. At the same time, the state-owned brands also expand their market share by increasing independent R & D investment and investment in M & A. in the future, with the downstream expansion, demand penetration, technology update and other factors, it is expected to accelerate the import substitution. -
艾媒咨询|2021全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:阿里健康,联合丽格,恒瑞医药,白云山,平安好医生,111集团,新氧,药明巨诺,盘龙药业,先导药业,好大夫在线,优健康,春雨医生,丁香医生,微医
受到人口老龄化、居民患病比例增加等因素影响,国家医疗费用支出不断增加,属于刚性需求;同时,随着人们对健康标准的不断提高以及互联网医疗技术的发展,大健康产业会在相当长的时期内持续保持增长态势。数据显示,2020年中国的大健康产业营收规模超过7万亿元,预计2021年将达8万亿元,增幅达8.1%。其中,得益于大健康产业发展以及疫情期间医药需求增长,生物制药、医疗器械两大细分领域表现良好,成为2020年中国投资热度较高的新经济行业,投资项目金额分别为919亿元和273亿元。
Affected by the aging population and the increasing proportion of residents, the national medical expenditure is increasing, which belongs to the rigid demand; At the same time, with the continuous improvement of people's health standards and the development of internet medical technology, the big health industry will continue to grow for a long time. According to the data, the revenue of China's big health industry will exceed 7 trillion yuan in 2020, and it is expected to reach 8 trillion yuan in 2021, an increase of 8.1%. Among them, thanks to the development of big health industry and the growth of pharmaceutical demand during the epidemic period, biopharmaceuticals and medical devices have performed well, becoming China's new economy industry with high investment enthusiasm in 2020, with investment projects of 91.9 billion yuan and 27.3 billion yuan respectively.
- 1
- 2
- 3
- 4
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告